Evidence map›Paper›PMID 40316940›Full record

Trial reportBMC cancer2025

Efficacy of photobiomodulation for the prevention and treatment of chemotherapy-induced oral mucositis in pediatric patients with hematologic cancers: a randomized clinical trial.

Fatemeh Lavaee, Fahimeh Rezazadeh, Ali Amanati, Asma Sookhakian, Mohammad Amin Amiri, Navid Dehghani, Kiarash Fereidouni

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatemeh LavaeeOral and Dental Disease Research Center, Department of Oral and Maxillofacial Medicine, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Fahimeh RezazadehOral and Dental Disease Research Center, Department of Oral and Maxillofacial Medicine, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali AmanatiClinical Research Development Center, Amir Oncology Teaching Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. ali_amanati_1356@yahoo.com.
Asma SookhakianPostgraduate Student, Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. asma.soukhakian@gmail.com.
Mohammad Amin Amiri *Oral and Dental Disease Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Navid Dehghani *Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Kiarash Fereidouni *Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral mucositis (OM) is a debilitating treatment-related complication that affects most children undergoing chemotherapy. This dual-arm clinical trial aimed to evaluate the efficacy of photobiomodulation (PBM) for prevention and photodynamic therapy (PDT) using indocyanine green (ICG) and low-level laser for treating methotrexate (MTX)-induced OM in pediatric patients with hematologic cancers.

methodsIn the prevention arm, patients were initially assigned to a control group (received no laser) and subsequently reassigned to a PBM group in their next cycle, allowing intra-patient comparison under similar chemotherapy protocols. In the treatment arm, patients diagnosed with OM were randomly assigned to either a control group (sham laser) or a PDT group.

resultsIn the prevention arm, PBM led to a significant reduction in the incidence of OM from 66.67% to 6.67% (p < 0.05). In the treatment arm, the PDT group showed a significant reduction in the scores of all scales (WHO, NCI, and WCCNR) at both 3 days and 5 days after starting the treatment compared to the control group (p < 0.05). Moreover, the reduction in the NCI score from the third to the fifth days after the starting treatment is higher in the PDT group compared to the control group (p < 0.05).

conclusionPBM appears to be a safe and effective approach for the prevention of MTX-induced OM in pediatric patients with hematologic cancers. Additionally, PDT using ICG and a low-level laser demonstrates promising results in treating OM lesions. Therefore, these findings highlight the efficacy of PBM for managing MTX-induced OM in this patient group.

trial registrationThe study has been registered on irct.behdasht.gov.ir on 4 December 2022 (Trial Registration Number: IRCT20120101008585N16).

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHematologic NeoplasmsLow-Level Light TherapyMethotrexatePhotochemotherapyStomatitisAdolescentChildChild, PreschoolFemaleHumansIndocyanine GreenMaleTreatment OutcomeIndocyanine GreenMethotrexateHematologyIndocyanine GreenLaser TherapyMucositisNeoplasmsPediatricsPhotobiomodulationPhotodynamic Therapy

Identifiers

PMID40316940
PMCPMC12049046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.